Board of Directors

  • Stephen C. McCluski

    Chairman of the Board

    Former Senior Vice President and Chief Financial Officer of Bausch & Lomb

    Stephen C. McCluski has been a director of ImmunoGen since April 2007, and the Chairman of the Board since November 2009. Mr. McCluski served as Senior Vice President and Chief Financial Officer of Bausch & Lomb Incorporated from 1995 to his retirement in 2007. Prior to that he served in various executive capacities at Bausch & Lomb and its subsidiaries from 1989 to 1995. Mr. McCluski is also a director of Standard Microsystems Corporation and of the James P. Wilmot Cancer Center of the University of Rochester.

  • Daniel M. Junius

    President and Chief Executive Officer of ImmunoGen, Inc.

    Daniel M. Junius has been a director of ImmunoGen since November 2008 and the President and Chief Executive Officer of the Company since January 2009. Mr. Junius served as President and Chief Operating Officer of ImmunoGen from July 2008 to December 2008, as Executive Vice President, Finance and Chief Financial Officer of ImmunoGen from 2006 to July 2008, and as Senior Vice President, Finance and Chief Financial Officer of ImmunoGen from 2005 to 2006.

    Mr. Junius served as Executive Vice President and Chief Financial Officer of New England Business Service, Inc. (NEBS) from 2002 to 2004 and as Senior Vice President and Chief Financial Officer of NEBS from 1998 to 2002. Prior to NEBS, he served as Vice President and Chief Financial of Nashua Corporation. Mr. Junius joined Nashua Corporation in 1984 and held financial management positions of increasing responsibility before becoming Chief Financial Officer in 1996.

  • Mark Goldberg, M.D.

    Senior Vice President of Product Development of Synageva BioPharma Corp.

    Mark Goldberg, M.D., has been a director of ImmunoGen since November 2011. Dr. Goldberg has served as Senior Vice President of Product Development for Synageva BioPharma Corp. since September 2011. Prior to that he served in various management capacities of increasing responsibility at Genzyme Corporation, from 1996 to 2011, most recently as Senior Vice President, Clinical Research and Global Therapeutic Head, Oncology, Genetic Health, and as Chairman of Genzyme's Early Product Review Board. Prior to joining Genzyme, he was a full-time staff physician at Brigham and Women's Hospital and the Dana-Farber Institute, where he still holds appointments. Dr. Goldberg is an Associate Professor of Medicine at Harvard Medical School. Dr. Goldberg holds a Doctor of Medicine degree from Harvard Medical School.

  • Dean Mitchell

    Executive Chairman of the Board of Covis Pharma Holdings S.a.r.l.

    Dean Mitchell has been a director of ImmunoGen since January 2012. Mr. Mitchell is Executive Chairman of the Board of Covis Pharma Holdings. He previously was President and CEO of Lux Biosciences, Inc., and also a director on its board. Prior to that he was President and CEO of Alpharma, Inc. and, before that, of Guilford Pharmaceuticals. Prior to joining Guilford in 2004, Mr. Mitchell held senior-level positions at Bristol-Myers Squibb, including President, International Pharmaceuticals and President, North America Primary Care. Prior to joining Bristol-Myers Squibb in 2001, Mr. Mitchell had a fourteen-year career with GlaxoSmithKline, Inc., becoming Senior Vice President, Clinical Development and Product Strategy in 2000. Mr. Mitchell is also a director of Intrexon Corporation and of Ista Pharmaceuticals.

  • Nicole Onetto, M.D.

    Deputy Director and Chief Scientific Officer of the Ontario Institute for Cancer Research

    Nicole Onetto, MD, has been a director of ImmunoGen since June 2005. Dr. Onetto has served as Deputy Director and Chief Scientific Officer of the Ontario Institute for Cancer Research since November 2011 and as Deputy Director of the Ontario Institute for Cancer Research from 2009-2011. Prior to this, she served as Senior Vice President and Chief Medical Officer of ZymoGenetics, Inc., from 2005 to 2009. She served as Executive Vice President and Chief Medical Officer at OSI Pharmaceuticals, Inc., from 2003 to 2005, and as Executive Vice President of OSI Pharmaceutical's Oncology business from 2002 to 2003. Prior to that she served as Senior Vice President, Medical Affairs, at Gilead Sciences, Inc., from 2000 to 2001. Dr. Onetto has a Doctor of Medicine degree from the University of Paris V, France and a M.Sc. in Pharmacology from the Univeristy of Montreal.

  • Kristine Peterson

    CEO, Valeritas, Inc.

    Kristine Peterson has been a director of ImmunoGen since January 2012. Ms. Peterson is CEO of Valeritas, Inc., and also a director on its board. She previously was Company Group Chairman, Biotech Business, at Johnson & Johnson, where she was responsible for research, development, manufacturing, and commercialization of oncology, immunology, and other biotechnology therapeutics for the company. Prior to joining J&J in 2004 as Executive VP, Pharmaceutical Group Strategic Marketing, Ms. Peterson had a twenty-year career with Bristol-Myers Squibb, rising through the organization to become Senior VP, Global Marketing before taking Senior VP and President roles at Biovail Corporation in 2003. Ms. Peterson is active in the Biotechnology Industry Organization (BIO) and also serves on the board of Amarin Corporation.

  • Howard H. Pien

    Former Chairman of the Board and Chief Executive Officer of Medarex, Inc.

    Mr. Pien has been a director of ImmunoGen since November 2009. He was the Chairman of the Board and Chief Executive Officer of Medarex, Inc. from 2007 to its acquisition by Bristol-Myers Squibb Company in 2009. Prior to that, he was a private consultant from 2006 to 2007. Prior to that, he was President and Chief Executive Officer of Chiron Corporation from 2003 to its acquisition by Novartis in 2006, and before that Mr. Pien held positions of increasing responsibility at GlaxoSmithKline and its predecessor, SmithKline Beecham, at Abbott Laboratories and at Merck & Co. He is also a director of Bellerophon, Juno, Sage and Vanda Pharmaceuticals and is the Chairman designee of Reckett Benkiser Pharmaceutical. Mr. Pien is also an advisor to the Life Sciences Practice of Warburg Pincus, a private equity firm. Mr. Pien's non-profit Board appointments include the industry associations BIO and PhRMA, as well as Oakland Children's Hospital and Fox Chase Hospital.

  • Joseph J. Villafranca, Ph.D.

    President, BioPharmaceutical Consultants LLC 

    Joseph J. Villafranca, Ph.D., has been a director of ImmunoGen since June 2004. Dr. Villafranca is President of BioPharmaceutical Consultants LLC. He previously was a Senior Vice President at the life sciences consulting firm, Tunnell Consulting, and an Executive Vice President at Neose Technologies, Inc., a biotechnology company. Prior to joining Neose in 2002, Dr. Villafranca served in executive positions at Bristol-Myers Squibb Company over a period of 11 years. Dr. Villafranca holds a Ph.D. in Biochemistry/Chemistry from Purdue University and completed his postdoctoral work at the Institute for Cancer Research in Philadelphia, Pennsylvania. Dr. Villafranca is also a director of ANIMA Cell Metrology.

  • Richard J. Wallace

    Former Senior Vice President for Research and Development at GlaxoSmithKline plc

    Richard J. Wallace has been a director of ImmunoGen since November 2007. Mr. Wallace served as a Senior Vice President for Research and Development at GlaxoSmithKline plc (GSK) from 2004 to his retirement in 2008. Prior to that he served in various executive capacities for GSK and its predecessor companies and their subsidiaries from 1992 to 2004. Mr. Wallace's experience prior to joining GSK included eight years with Bristol-Myers Squibb Company and seven years at Johnson & Johnson in assignments spanning marketing, sales, manufacturing and general management. Mr. Wallace is also a director of GNC Corporation.

Last updated October 1, 2014